GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (STU:EV00) » Definitions » EPS (Basic)

Evoke Pharma (STU:EV00) EPS (Basic) : €-2.16 (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Evoke Pharma EPS (Basic)?

Evoke Pharma's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was €-0.54. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.16.

Evoke Pharma's EPS (Diluted) for the three months ended in Dec. 2023 was €-0.54. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.16.

Evoke Pharma's EPS without NRI for the three months ended in Dec. 2023 was €-0.54. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -2.16.

During the past 3 years, the average EPS without NRI Growth Rate was 28.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 16.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 21.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Evoke Pharma's highest 3-Year average EPS without NRI Growth Rate was 36.20% per year. The lowest was -1.40% per year. And the median was 16.25% per year.


Evoke Pharma EPS (Basic) Historical Data

The historical data trend for Evoke Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma EPS (Basic) Chart

Evoke Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.46 -5.13 -2.81 -2.47 -2.14

Evoke Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.50 -0.63 -0.52 -0.48 -0.54

Evoke Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Evoke Pharma's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-7.145-0)/3.343
=-2.14

Evoke Pharma's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.822-0)/3.343
=-0.55

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evoke Pharma  (STU:EV00) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Evoke Pharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Evoke Pharma (STU:EV00) Business Description

Traded in Other Exchanges
Address
420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma (STU:EV00) Headlines

No Headlines